CAS
ATOS icon

CTC Alternative Strategies’s Atossa Therapeutics ATOS Stock Holding History

CTC Alternative Strategies’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,420
Closed -$65.3K – 191
2024
Q1 		$65.3K Buy
+2,420
New +$38.9K 0.04% 94

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

CTC Alternative Strategies's ATOS Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Atossa Therapeutics (ATOS) in Q2 2024, closing a stake of 2,420 shares — an estimated $65.3K sold.

CTC Alternative Strategies first reported a position in ATOS in Q1 2024 and held it in 1 quarter. The position peaked at $65.3K in Q1 2024. 77 funds tracked by Wall St. Rank hold ATOS as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Atossa Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 2,420 Atossa Therapeutics shares in Q2 2024, an estimated $65.3K.
  • CTC Alternative Strategies first reported a position in Atossa Therapeutics in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Atossa Therapeutics position peaked at $65.3K in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.